KR20140029426A - 비강내 벤조디아제핀 약제학적 조성물 - Google Patents

비강내 벤조디아제핀 약제학적 조성물 Download PDF

Info

Publication number
KR20140029426A
KR20140029426A KR1020137028968A KR20137028968A KR20140029426A KR 20140029426 A KR20140029426 A KR 20140029426A KR 1020137028968 A KR1020137028968 A KR 1020137028968A KR 20137028968 A KR20137028968 A KR 20137028968A KR 20140029426 A KR20140029426 A KR 20140029426A
Authority
KR
South Korea
Prior art keywords
diazepam
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
monoethyl ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137028968A
Other languages
English (en)
Korean (ko)
Inventor
게리 브림
모이세 아. 카이랄라
백명기
조재훈
장혜진
Original Assignee
아코르다 쎄라퓨틱스 인코포레이티드
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아코르다 쎄라퓨틱스 인코포레이티드, 에스케이바이오팜 주식회사 filed Critical 아코르다 쎄라퓨틱스 인코포레이티드
Publication of KR20140029426A publication Critical patent/KR20140029426A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020137028968A 2011-03-31 2012-03-30 비강내 벤조디아제핀 약제학적 조성물 Ceased KR20140029426A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161469940P 2011-03-31 2011-03-31
US61/469,940 2011-03-31
PCT/US2012/031453 WO2012135619A2 (en) 2011-03-31 2012-03-30 Intranasal benzodiazepine pharmaceutical compositions

Publications (1)

Publication Number Publication Date
KR20140029426A true KR20140029426A (ko) 2014-03-10

Family

ID=46928023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028968A Ceased KR20140029426A (ko) 2011-03-31 2012-03-30 비강내 벤조디아제핀 약제학적 조성물

Country Status (15)

Country Link
US (3) US20120252793A1 (enExample)
EP (1) EP2691100A4 (enExample)
JP (1) JP2014509655A (enExample)
KR (1) KR20140029426A (enExample)
CN (1) CN103619338B (enExample)
AR (1) AR085927A1 (enExample)
AU (1) AU2012236334B2 (enExample)
BR (1) BR112013024968A2 (enExample)
CA (1) CA2831308A1 (enExample)
MX (1) MX357800B (enExample)
PH (2) PH12013501915A1 (enExample)
RU (2) RU2018135967A (enExample)
SG (2) SG193958A1 (enExample)
TW (1) TWI601532B (enExample)
WO (1) WO2012135619A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5929800B2 (ja) * 2012-04-03 2016-06-08 コニカミノルタ株式会社 定着液および画像形成方法
AU2018275686B2 (en) * 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
MX2020013192A (es) 2018-06-04 2021-08-16 Arcutis Inc Metodo y formulacion para mejorar el tiempo de retraso de penetracion en la piel de roflumilast.
CN111529489A (zh) * 2020-04-17 2020-08-14 山东省药学科学院 一种含有地西泮的鼻腔喷雾剂
EP4255393B1 (en) 2020-12-04 2025-05-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
MX2024008192A (es) 2021-12-28 2024-09-10 Arcutis Biotherapeutics Inc Espumas en aerosol de roflumilast topico.
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE229817T1 (de) * 1996-10-24 2003-01-15 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
EP1196156B1 (en) * 1999-07-26 2008-04-30 SK Holdings Co., Ltd. Transnasal anticonvulsive compositions
DK1539285T4 (da) * 2002-09-03 2012-01-02 Pharmacure Health Care Ab Næsesprayer
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
US8946208B2 (en) * 2007-08-31 2015-02-03 Archimedes Development Limited Non-aqueous pharmaceutical composition
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
WO2011034920A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating seizure disorders

Also Published As

Publication number Publication date
SG193958A1 (en) 2013-11-29
US20140128381A1 (en) 2014-05-08
RU2013148120A (ru) 2015-05-10
US20170151258A1 (en) 2017-06-01
BR112013024968A2 (pt) 2016-12-20
PH12017501688A1 (en) 2018-09-10
CA2831308A1 (en) 2012-10-04
JP2014509655A (ja) 2014-04-21
MX357800B (es) 2018-07-25
AU2012236334A1 (en) 2013-10-10
AU2012236334B2 (en) 2017-02-16
CN103619338A (zh) 2014-03-05
HK1195252A1 (zh) 2014-11-07
EP2691100A4 (en) 2014-09-24
WO2012135619A3 (en) 2012-11-22
MX2013011336A (es) 2013-12-16
AR085927A1 (es) 2013-11-06
RU2018135967A (ru) 2018-11-14
US20120252793A1 (en) 2012-10-04
SG10201602176RA (en) 2016-04-28
TWI601532B (zh) 2017-10-11
TW201302204A (zh) 2013-01-16
EP2691100A2 (en) 2014-02-05
CN103619338B (zh) 2016-06-22
PH12013501915A1 (en) 2019-11-29
WO2012135619A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
AU2012236334B2 (en) Intranasal benzodiazepine pharmaceutical compositions
US11717571B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
RU2692245C2 (ru) Интраназальные композиции дексмедетомидина и способы их применения
US20220273672A1 (en) Orally inhaled and nasal benzodiazepines
US20160199296A1 (en) Nasal formulations of benzodiazepine
US20250302741A1 (en) Intranasal olanzapine formulations and methods of their use
CA3088989C (en) Intranasal epinephrine formulations and methods for the treatment of disease
US20060039869A1 (en) Intranasal delivery of antipsychotic drugs
US20250352554A1 (en) Intranasal olanzapine formulations and methods of their use
HK1195252B (en) Intranasal benzodiazepine pharmaceutical compositions
HK40005168B (en) Orally inhaled and nasal benzodiazepines
HK40005168A (en) Orally inhaled and nasal benzodiazepines

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131031

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170310

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180108

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180718

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180108

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I